Skip to main content
Article thumbnail
Location of Repository

The Dual Role of Smad7 in the Control of Cancer Growth and Metastasis

By Carmine Stolfi, Irene Marafini, Veronica De Simone, Francesco Pallone and Giovanni Monteleone


Smad7 was initially identified as an inhibitor of Transforming growth factor (TGF)-β due mainly to its ability to bind TGF-β receptor type I and prevent TGF-β-associated Smad signaling. More recently, it has been demonstrated that Smad7 can interact with other intracellular proteins and regulate also TGF-β-independent signaling pathways thus making a valid contribution to the neoplastic processes in various organs. In particular, data emerging from experimental studies indicate that Smad7 may differently modulate the course of various tumors depending on the context analyzed. These observations, together with the demonstration that Smad7 expression is deregulated in many cancers, suggest that therapeutic interventions around Smad7 can help interfere with the development/progression of human cancers. In this article we review and discuss the available data supporting the role of Smad7 in the modulation of cancer growth and progression

Topics: TGF-β, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, epithelial-mesenchimal transition, hepatocellular carcinoma, melanoma, genome-wide association study, carcinogenesis, Chemistry, QD1-999, Science, Q, DOAJ:Chemistry (General), DOAJ:Chemistry, Biology (General), QH301-705.5
Publisher: MDPI AG
Year: 2013
DOI identifier: 10.3390/ijms141223774
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.